U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07472166) titled 'Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate' on March 09.
Brief Summary: This study aims to evaluate the efficacy of Tofacitinib compared to Methotrexate (MTX) in reducing skin thickening in patients with diffuse cutaneous systemic sclerosis (dcSSc). Systemic sclerosis is a chronic autoimmune disease characterized by skin fibrosis and internal organ involvement. Despite existing treatments, many patients continue to experience progressive skin and joint symptoms.
Tofacitinib, a Janus kinase (JAK) inhibitor, has shown potential benefit in reducing inflamm...